NCT02024477View on ClinicalTrials.gov

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2017

Conditions
Type 2 Diabetes
Interventions
DRUG

Saxagliptin

5 mg tablet once daily for 12 weeks

DRUG

Placebo

1 tablet daily for 12 weeks

Trial Locations (1)

20037

Medical Faculty Associates Inc, Washington D.C.

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

George Washington University

OTHER